PERSEPHONE: A randomised phase 3 non-inferiority trial of 6 versus 12 months (m) of adjuvant trastuzumab in patients with HER2 positive (+) early breast cancer (EBC)Helena Earl,Louise Hiller,Anne-Laure Vallier, Shrushma Loi, Donna Howe,Helen Higgins,Karen McAdam,Luke Hughes-Davies,Adrian Harnett,Mei-Lin Ah-See,Richard Simcock,Daniel Rea,Janine Mansi,Jean Abraham,Carlos Caldas,Claire Hulme,David Miles,Andrew Wardley,David Cameron,Janet DunnBRITISH JOURNAL OF CANCER（2018）引用 0|浏览41暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
